ストックスクリーナーアプリを入手
7.23
1.12%
0.08
前日終値:
$7.15
開ける：
$7.19
24時間の取引高:
179.77K
Relative Volume:
0.67
時価総額：
$186.55M
収益：
$34.26M
当期純損益:
$-46.61M
株価収益率:
-1.3956
EPS:
-5.1806
ネットキャッシュフロー:
$-62.01M
1週間 パフォーマンス:
-0.55%
1か月 パフォーマンス:
-8.60%
6か月 パフォーマンス:
+44.60%
1年 パフォーマンス:
+55.82%
1日の値動き範囲:
$7.18
$7.40
1週間の範囲:
$6.6601
$7.63
52週間の値動き範囲:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
名前
Precision Biosciences Inc
セクター
電話
919-314-5512
住所
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
7.23 | 184.49M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | 開始されました | Guggenheim | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-06-09 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | 再開されました | BTIG Research | Buy |
| 2020-04-03 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-05 | 開始されました | Stifel | Buy |
| 2020-02-25 | 開始されました | William Blair | Outperform |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | H.C. Wainwright | Buy |
| 2019-04-22 | 開始されました | Barclays | Overweight |
| 2019-04-22 | 開始されました | Goldman | Buy |
| 2019-04-22 | 開始されました | JP Morgan | Overweight |
| 2019-04-22 | 開始されました | Jefferies | Buy |
すべてを表示
Precision Biosciences Inc (DTIL) 最新ニュース
Precision Biosciences (DTIL) director gains 21,000 shares as RSUs vest into common stock - Stock Titan
Director at Precision BioSciences (DTIL) sees 21,000 RSUs vest into common stock - Stock Titan
Director Melinda Brown receives 21,000 DTIL shares as RSUs vest (DTIL) - Stock Titan
Precision BioSciences (DTIL) director gains 21,000 shares from RSU vesting - Stock Titan
Precision Biosciences (NASDAQ: DTIL) director’s 21,000 RSUs vest into shares - Stock Titan
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINA - pharmiweb.com
Precision BioSciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 - Yahoo Finance
Precision BioSciences stock (US74019P1084): earnings miss and volatile recovery in gene editing play - AD HOC NEWS
Precision BioSciences stock (US74019P1084): gene-editing player in focus after fresh ECUR?506 trial - AD HOC NEWS
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Australia
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - Yahoo Finance
Precision BioSciences stock (US74019P1084): Q3 2024 earnings report shows EPS loss - AD HOC NEWS
Precision BioSciences exits substantial shareholder role in Imugene - TipRanks
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Precision BioSciences (DTIL) reports Q1 loss, tops revenue estimates - MSN
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Guggenheim Initiates Precision BioSciences(DTIL.US) With Buy Rating, Announces Target Price $19 - Moomoo
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Precision BioSciences Q1 2026 earnings preview - MSN
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Q1 2026 loss narrows as gene-editing pipeline advances - Stock Titan
Precision BioSciences 1Q 2026: Revenue $10.8M, EPS $(0.75) — 10-Q Summary - TradingView
Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan
DTIL: Advanced gene editing trials and improved financials, with strong cash runway through 2028 - TradingView
Precision BioSciences: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Precision BioSciences, Inc. Q1 Revenue USD 10.838 Million Vs. IBES Estimate USD 4.05 Million - TradingView
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Precision BioSciences (DTIL) Set to Report Q1 2026 Earnings with Analyst Expectations - GuruFocus
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday - MarketBeat
Precision BioSciences Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Precision Biosciences Inc (DTIL) 財務データ
収益
当期純利益
現金流量
EPS
Precision Biosciences Inc (DTIL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):